Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
61.44
-3.22 (-4.98%)
At close: Dec 5, 2025, 4:00 PM EST
62.20
+0.76 (1.24%)
After-hours: Dec 5, 2025, 7:29 PM EST
Arrowhead Pharmaceuticals Employees
Arrowhead Pharmaceuticals had 711 employees as of September 30, 2025. The number of employees increased by 102 or 16.75% compared to the previous year.
Employees
711
Change (1Y)
102
Growth (1Y)
16.75%
Revenue / Employee
$1,166,594
Profits / Employee
-$2,294
Market Cap
8.34B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ARWR News
- 3 days ago - Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia - Business Wire
- 4 days ago - Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences - Business Wire
- 8 days ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript - Seeking Alpha
- 9 days ago - Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today - The Motley Fool
- 10 days ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results - Business Wire
- 11 days ago - Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - Business Wire
- 16 days ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome Transcript - Seeking Alpha